Evidence map›Paper›PMID 27386438›Full record

ArticleInternational journal of molecular and cellular medicine2016

Orosomucoid-1 Expression in Ameloblastoma Variants.

Alejandro García-Muñoz, Ronell Bologna-Molina, Mario A Rodríguez, Rodrigo Liceága-Reyes, Jose Eduardo Farfán-Morales, Saray Aranda-Romo, Nelly Molina-Frechero, Rogelio González-González

Open access · greenAbstract read
In one paragraph

Article in International journal of molecular and cellular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Expression of parathyroid hormone related protein (PTHRP) in ameloblastomas.Journal of clinical and experimental dentistry · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alejandro García-MuñozLaboratorio de Investigación en Odontología, ALMARAZ/UBIMED, FES Iztacala, UNAM. State of Mexico, Mexico.
Ronell Bologna-MolinaMolecular Pathology, Universidad de la República (UDELAR), Montevideo, Uruguay.
Mario A RodríguezDepartment of Infectomics and Molecular Pathogenesis, CINVESTAV-IPN, México, D.F, México.
Rodrigo Liceága-ReyesMaxillofacial Surgery Department. Hospital Juárez de México, México D.F, México.
Jose Eduardo Farfán-MoralesInstituto Nacional de Pediatría, México D.F, México.
Saray Aranda-RomoBiochemistry, Microbiology and Pathology Laboratory, Faculty of Stomatology, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
Nelly Molina-FrecheroHealth Care Department, Universidad Autónoma Metropolitana, Xochimilco, UAM, México City, Mexico.
Rogelio González-GonzálezDepartment Research, School of Dentistry, Universidad Juárez del Estado de Durango, México.
Center for Research and Advanced Studies of the National Polytechnic Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Odontogenic tumors constitute a group of heterogeneous lesions of benign and malignant neoplasms with variable aggressiveness. Ameloblastomas are a group of benign but locally invasive neoplasms that occur in the jaws and are derived from epithelial elements of the tooth-forming apparatus. We previously described orosomucoid-1 protein expression in odontogenic myxomas. However, whether orosomucoid-1 is expressed in other odontogenic tumors remains unknown. Since orosomucoid-1 belongs to a group of acute-phase proteins and has many functions in health and disease, we identified and analyzed orosomucoid-1 expression in ameloblastoma variants and ameloblastic carcinoma using western blot and immunohistochemical techniques. Thirty cases of ameloblastoma were analyzed for orsomucoid-1; five specimens were fresh for western blot study (four benign ameloblastomas and one ameloblastic carcinoma), and 25 cases of benign ameloblastoma for immunohistochemical assays. Orosomucoid-1 was widely expressed in each tumor variant analyzed in this study, and differential orosomucoid-1 expression was observed between benign and malignant tumor. Orosomucoid-1 may play an important role in the behavior of ameloblastomas and influence the biology and development of the variants of this tumor.

Indexed as

ameloblastic carcinomaameloblastomaodontogenic tumorsOrosomucoid-1

Identifiers

PMID27386438
PMCPMC4916783
OpenAlexW2256497766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.